The Journal of Organic Chemistry
Article
concentrated under reduced pressure. The residue was purified by
column chromatography (1−3% MeOH in CH2Cl2), affording the
product 2 (564 mg, 84%) as a yellow foam. Rf 0.36 (5% MeOH in
CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 9.6 Hz, 2H, Ar),
8.21−7.99 (m, 8H, Ar, NH), 7.82 (d, 1H, J = 0.6 Hz, H6), 7.67 (s, 1H,
H5-triazole), 7.52−7.33 (m, 9H, Ar), 7.25−7.03 (m, 4H, Ar), 6.24 (dd,
1H, J = 5.1, 9.6 Hz, H1′), 4.16 (dd, 1H, J = 8.8, 13.0 Hz, H6′), 3.91−
3.80 (m, 2H, H5′, H6′), 3.48 (s, 1H, H4′), 3.35 (d, J = 4.8 Hz, 1H,
H3′), 2.05 (s, 3H, CH3), 2.00 (m, 1H, H2′), 1.91 (m, 1H, H2′), 0.68
(s, 9H, (CH3)3), −0.19 (s, 3H, CH3Si), −0.29 (s, 3H, CH3Si); 13C
NMR (75 MHz, CDCl3) δ 163.7 (C4), 152.2, 152.0 (Ar), 150.3 (C2),
147.4 (C4-triazole), 146.2 (Ar), 135.7 (C6), 131.5, 131.4, 131.0, 130.9,
130.7, 130.5, 128.2, 128.1, 128.0, 127.8, 127.7, 127.4, 127.1, 126.2,
125.5, 125.5, 125.2, 125.1, 124.9, 124.8, 124.7, 124.2, 124.1, 124.0,
122.9, 122.5, 117.6, 117.2 (Ar + C5-triazole), 111.2 (C5), 86.8 (C4′),
84.9 (C1′), 78.9 (C-Ar3), 73.2 (C3′), 72.2 (C5′), 50.3 (C6′), 41.0
(C2′), 25.7 ((CH3)3), 17.7 (CSi), 12.8 (CH3), −4.5, −4.7 (CH3Si);
HR-ESI MS m/z 916.3504 ([M + Na]+, C54H51N5O6SiNa+ calcd
916.3501).
CH2Cl2 (3 × 10 mL). The combined organic phases were dried
(Na2SO4) and concentrated under reduced pressure. The residue was
purified by column chromatography (50−100% EtOAc, 0.5% pyridine
in petroleum ether) to afford the product 6 (112 mg, 79%) as a yellow
foam; Rf 0.36 (5% MeOH in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ
8.78 (s, 1H, NH), 8.32 (d, 1H, J = 9.3 Hz, pyrene), 8.16 (s, 1H, H5-
triazole), 8.10−7.74 (m, 9H, pyrene, H6), 7.44−7.13 (m, 9H, DMT),
6.84 (d, 4H, J = 8.6 Hz, DMT), 6.43 (d, 1H, J = 5.3 Hz, H1′), 5.36 (d,
1H, J = 8.2 Hz, H5), 5.25 (t, 1H, J = 5.7 Hz, H2′), 4.90 (dd, 1H, J =
5.9, 11.8 Hz, H3′), 4.53 (m, 1H, H4′), 4.21 (3′−OH), 3.78 (s, 6H,
OCH3), 3.56 (m, 2H, H5′); 13C NMR (101 MHz, CDCl3) δ 162.7
(C4), 158.99, 158.97 (DMT), 150.4 (C2), 147.4 (C4-triazole), 144.4
(DMT), 139.4 (C6), 135.3, 135.1 (DMT), 131.5, 131.3, 130.7, 130.32,
130.27, 128.42, 128.38, 128.1, 127.4, 127.3, 127.0, 126.1, 125.5, 125.3,
124.94, 124.90, 124.87, 124.5, 124.2, 124.1 (DMT, pyrene, C5-
triazole), 113.6 (DMT), 103.2 (C5), 87.6 (C-Ph3), 87.0 (C1′), 84.8
(C4′), 71.0 (C3′), 66.6 (C2′), 62.4 (C5′), 55.4 (OCH3). HRMS-ESI:
m/z 798.2948 ([M + H]+, C48H39N5O7H+ calcd 798.2922).
3′-O-(2-Cyanoethoxy-N,N-diisopropylaminophosphinyl)-5′-
O-(4,4′-dimethoxytrityl)-2′-(4-(pyren-1-yl)-1,2,3-triazole-1-yl)-
2′-deoxyuridine (7). Nucleoside 6 (184 mg, 0.23 mmol) was
coevaporated twice with anhydrous DCE and dissolved in the same
solvent (4.0 mL). N,N-Diisopropylethylamine (0.41 mL, 2.35 mmol)
and 2-cyanoethyl-N,N-diisopropylamino chlorophosphite (0.11 mL,
0.49 mmol) were added, and the reaction mixture was stirred at room
temperature for 4 h. Ethanol (1.5 mL) and CH2Cl2 (20 mL) were
added, and the solution was washed with a saturated aqueous solution
of NaHCO3 (15 mL). The aqueous phase was extracted with CH2Cl2
(2 × 10 mL), and the combined organic phases were dried (Na2SO4)
and concentrated under reduced pressure. The residue was purified by
column chromatography (0−100% EtOAc, 0.5% pyridine in petroleum
ether). The residue was precipitated three times from a solution in
EtOAc (1.5 mL) poured into cold petroleum ether (70 mL) to afford
the product 7 (111 mg, 48%) as a light yellow foam; Rf 0.59 (5%
MeOH in CH2Cl2); 31P NMR (162 MHz, CDCl3) δ 151.8, 150.2
(3:2). HRMS-ESI: m/z: 1020.3857 ([M + Na]+, C57H56N7O8PNa+
calcd 1020.3821).
5′-O-Pixyl-5′(S)-C-[(4-(pyren-1-yl)-1,2,3-triazol-1-yl)methyl]-
thymidine (3). Nucleoside 2 (373 mg, 0.42 mmol) was dissolved in
anhydrous THF (6.0 mL), and a 1.0 M solution of TBAF in THF
(0.42 mL, 0.42 mmol) was added. The reaction mixture was stirred for
3 h at room temperature. CH2Cl2 (20 mL) was added, and the
resulting solution was washed with a saturated aqueous solution of
NaHCO3 (15 mL). The aqueous phase was extracted with CH2Cl2 (3
× 10 mL), and the combined organic phases were washed with water
(20 mL), dried (Na2SO4), and concentrated under reduced pressure.
The residue was purified by column chromatography (0−10% MeOH,
0.5% pyridine in CH2Cl2) to afford the product 3 (267 mg, 82%) as a
1
light yellow foam; Rf 0.56 (10% MeOH in CH2Cl2); H NMR (400
MHz, CDCl3) δ 8.59 (d, 1H. J = 9.3 Hz, Ar), 8.51 (s, 1H, NH), 8.24−
7.99 (m, 8H, Ar), 7.66 (s, 1H, H5-triazole), 7.56−7.00 (m, 14H, H6,
Ar), 6.13 (t, 1H, J = 6.6 Hz, H1′), 4.19 (m, 1H, H6′), 4.03 (m, 1H,
H6′), 3.92 (m, 1H, H5′), 3.73 (m, 1H, H3′), 3.50 (t, 1H, J = 4.2 Hz,
1H, H4′), 2.26−2.06 (m, 3H, 3′−OH, H2′), 2.00 (s, 3H, CH3); 13C
NMR (101 MHz, CDCl3) δ 163.6 (C4), 152.2, 152.1 (Ar), 150.2
(C2), 147.6 (C4-triazole), 146.5 (Ar), 136.1 (C6), 131.6, 131.40,
131.38 131.0, 130.8, 130.5, 128.6, 128.4, 128.2, 128.1, 127.7, 127.5,
127.2, 126.3, 125.7, 125.4, 125.2, 125.1, 125.0, 124.9, 124.7, 124.4,
124.2, 123.8, 122.8, 122.7, 117.5, 117.0 (Ar, C5-triazole), 111.4 (C5),
85.0 (C4′), 84.2 (C1′), 78.4 (C-Ar3), 71.4 (C4′), 70.2 (C3′), 50.5
(C6′), 40.1 (C2′), 12.9 (CH3). HR-ESI MS m/z 802.2642 ([M +
Na]+, C48H37N5O6Na+ calcd 802.2637).
3′-O-(2-Cyanoethoxy-N,N-diisopropylaminophosphinyl)-5′-
O-pixyl-5′(S)-C-[(4-(pyren-1-yl)-1,2,3-triazol-1-yl)methyl]-
thymidine (4). To a solution of 3 (300 mg, 039 mmol) in anhydrous
CH2Cl2 (4 mL) were added N,N-diisopropylethylamine (0.26 mL,
1.50 mmol) and 2-cyanoethyl-N,N-diisopropylamino chlorophosphite
(0.20 mL, 0.90 mmol) under Ar atmosphere. The reaction mixture was
stirred at room temperature for 2 h. CH2Cl2 (30 mL) was added, and
the mixture was washed with a 10% aqueous solution of NaHCO3.
The aqueous phase was extracted with CH2Cl2 (3 × 30 mL), and the
combined organic phase was dried (Na2SO4) and concentrated under
reduced pressure. The residue was purified by column chromatog-
raphy (0−20% (CH3)2CO, 0.25% pyridine in CH2Cl2) to give the
product 4 (260 mg, 69%) as a yellow foam: Rf 0.27, 0.36 (10%
(CH3)2CO in CH2Cl2); 31P NMR (162 MHz, CDCl3) δ 151.61,
151.47; HR-ESI MS m/z 1002.3718 ([M + Na]+, C57H54N7O7PNa+
calcd 1002.3714).
5′-O-(4,4′-Dimethoxytrityl)-2′-C-(prop-2-yn-1-yl)-2′-deoxy-
uridine (9). Nucleoside 820 (165 mg, 0.62 mmol) was coevaporated
with anhydrous pyridine (2 × 5 mL) and redissolved in the same
solvent (10 mL). 4,4′-Dimethoxytrityl chloride (270 mg, 0.80 mmol)
was added, and the reaction mixture was stirred at room temperature
for 16 h. Ethanol (1.0 mL) was added, and the mixture was
concentrated under reduced pressure. The residue was dissolved in
CH2Cl2 (20 mL), and the mixture was washed with a saturated
aqueous solution of NaHCO3 (2 × 15 mL). The combined aqueous
phase was extracted with CH2Cl2 (2 × 15 mL), and the combined
organic phase was dried (Na2SO4), concentrated under reduced
pressure, and coevaporated with a mixture of toluene and EtOH (15
mL, 1:2, v/v). The residue was purified by column chromatography
(0−5% MeOH in CH2Cl2, v/v) to afford the product 9 (280 mg, 79%)
1
as a slightly yellow solid. Rf 0.5 (5% MeOH in CH2Cl2); H NMR
(400 MHz, DMSO-d6) δ 11.32 (br s, 1H, NH), 7.53 (d, 1H, J = 8.4
Hz, H6), 7.40−7.24 (m, 9H, Ar), 6.92−6.89 (m, 4H, Ar), 5.92 (d, 1H,
J = 8.0 Hz, H1′), 5.50 (d, 1H, J = 5.2 Hz, 3′−OH), 5.47 (d, 1H, J = 8.4
Hz, H5), 4.19 (m, 1H, H3′), 4.14 (m, 1H, H4′), 3.74 (s, 6H, OCH3),
3.25 (dd, 1H, J = 4.4, 10.0 Hz, H5′), 3.15 (dd, 1H, J = 4.4, 10.0 Hz,
H5′), 2.78 (t, 1H, J = 2.4 Hz, CCH), 2.48−2.41 (m, 2H, H2′, CH2),
2.23 (m, 1H, CH2); 13C NMR (100 MHz, DMSO-d6) δ 162.8 (C4),
158.0 (DMT), 150.6 (C2), 144.5 (C6), 140.2, 135.2, 135.1, 129.6,
130.2, 127.8, 127.5, 126.6, 113.1 (DMT), 101.8 (C5), 86.8 (C1′), 85.8
(CPh3), 84.9 (C4′), 81.7 (CCH), 71.5 (C3′), 71.4 (CCH), 63.7
(C5′), 54.9 (OCH3), 45.9 (C2′), 13.6 (CH2CCH); HRMS-ESI: m/
z: 591.2094 ([M + Na]+, C33H32N2O7Na+ calcd 591.2107).
5′-O-(4,4′-Dimethoxytrityl)-2′-(1-(pyren-1-yl)-1,2,3-triazole-
4-yl)methyl)-2′-deoxyuridine (10). Nucleoside 9 (100 mg, 0.17
mmol) was dissolved in THF:H2O:tBuOH (10 mL, 3:1:1, v/v/v). To
the solution was added an aqueous solution of sodium ascorbate (1 M,
0.6 mL, 0.6 mmol), an aqueous solution of CuSO4 (0.6 mL, 7.5% w/v,
0.17 mmol), and 1-azidopyrene (100 mg, 0.40 mmol). The mixture
5′-O-(4,4′-Dimethoxytrityl)-2′-(4-(pyren-1-yl)-1,2,3-triazole-
1-yl)-2′-deoxyuridine (6). Nucleoside 5 (102 mg, 0.18 mmol), 1-
ethynylpyrene (51 mg, 0.23 mmol), and TBTA (17 mg, 0.05 mmol)
were dissolved in a mixture of THF:H2O:pyridine (6:3:2, 1.7 mL), and
the solution was degassed under argon. A solution of sodium ascorbate
(14 mg, 0.07 mmol) and CuSO4·5H2O (9 mg, 0.04 mmol) in water
(0.25 mL) was added, and the reaction mixture was stirred at room
temperature for 24 h. The reaction mixture was diluted with CH2Cl2
(15 mL), and the mixture was washed with a saturated aqueous
solution of NaHCO3 (10 mL). The aqueous phase was extracted with
9571
dx.doi.org/10.1021/jo301571s | J. Org. Chem. 2012, 77, 9562−9573